ClinicalTrials.gg
CompletedNCT02227238Updated Mar 13, 2023Results posted

Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment

A Phase 3 interventional study of DTG and LPV/RTV in HIV Infections, sponsored by ViiV Healthcare. Completed at 59 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-13.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
627
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 55 studies testing dolutegravir in HIV Infections — 7 open to participants now, 9 under way, 4 of them phase 3. Dolutegravir · HIV Infections.

Enrollment
9th of 55
627 · median 126
Started
2014
with 3 others
Phase 3
21 of 55
2 open now
Registered
16th of 55
by date
Lead sponsor
26 of 55
ViiV Healthcare

Among the 55 studies testing dolutegravir in HIV Infections, this one is the 9th largest by enrollment, is one of 4 that started in 2014, is one of 21 in phase 3, and was the 16th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

7 of the 55 studies testing dolutegravir in HIV Infections are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dolutegravir

Dolutegravir: first FDA approval 2013 (TIVICAY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing dolutegravir in HIV Infections, or all of them as a file.
02

Study summary

For treatment of human immunodeficiency virus type 1(HIV-1), publicly funded programmes tend to follow World Health Organization (WHO) guidelines to use a non-nucleoside reverse transcriptase inhibitor (NNRTI) combined with two nucleoside reverse transcriptase inhibitors (NRTIs) for first-line antiretroviral therapy (ART); however, there is a need for further data on the best treatment options for people with HIV-1 who have virological failure with this first-line regimen. The number of patients failing on their first-line regimen is increasing thereby requiring a switch to second-line treatment to reduce accumulation of drug-resistance mutations, disease progression, HIV transmission, and death. WHO guidelines recommend second-line antiretroviral therapy for adults consisting of two NRTIs + a ritonavir-boosted protease inhibitor (PI); atazanavir (ATV) plus ritonavir (RTV) or lopinavir (LPV)/RTV are the preferred boosted PI options. This study is conducted to demonstrate non-inferior antiviral activity at 48 weeks of a dolutegravir (DTG) containing regimen compared to a WHO-recommended standard of care regimen for second line treatment, LPV/RTV + two NRTIs, in HIV-1 infected patients failing first line therapy. This study comprises of a Screening Phase (approximately 28 to 42 days), a Randomized Phase (Day 1 to Week 48 plus a 4-week treatment extension), and a Continuation Phase. Approximately 612 subjects will be randomized 1:1 to receive DTG 50 milligram (mg) once daily or LPV/RTV (800/200 mg once daily or 400/100 mg twice daily, in accordance with investigator decision and local label), each added to an investigator selected background regimen of two NRTIs at least one of which needs to be fully active based on viral resistance testing at Screening. Subjects randomized to the LPV/RTV arm will either (i) continue receiving LPV/RTV and complete the study after the 4-week treatment extension at Week 52, or (ii) switch to the DTG arm prior to study completion at Week 52 and continue to have access to DTG in the Continuation Phase. Subjects randomized to receive DTG who successfully complete 52 weeks of treatment and subjects originally randomized to receive LPV/RTV but switched to DTG prior to Week 52 will continue to have access to DTG until it is either locally approved and commercial supplies are available to patients or the patient no longer derives clinical benefit, or the patient meets a protocol-defined reason for discontinuation.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • integrase inhibitor
  • non-inferiority
  • dolutegravir
  • lopinavir/ritonavir
  • second-line treatment
  • HIV-1
  • antiretroviral therapy-experienced
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -1 infected subjects >=18 years of age.
  • A female subject may be eligible to enter and participate in the study if she:

is of non- defined as either (12 months of spontaneous amenorrhea and >=45 years of age) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy, or bilateral oophorectomy or, is of child-bearing potential, with a negative pregnancy test at both Screening and Day 1 and agrees to use one of the protocol-defined methods of to avoid pregnancy throughout the study and for at least 2 weeks after discontinuation of all study medication.

  • HIV-1 infection as documented by HIV-1 RNA >=400 c/mL at Screening.
  • Subject has been on a treatment regimen consisting of an NNRTI plus two NRTIs for at least 6 months and is currently experiencing virologic failure to this first-line regimen defined as two consecutive (>=7 days apart) HIV-1 RNA results of >=400 c/mL.
  • Subjects must receive at least one fully active agent within the dual-NRTI background regimen for second line treatment. Fully active is defined by the Screening genotypic resistance report of the central laboratory (or a laboratory contracted by the central laboratory) showing no evidence of full or of partial resistance for a given NRTI which will be taken on study.
  • Subject is PI-naïve and Integrase inhibitor (INI)-naïve, defined as no prior or current exposure to any PI or INI.
  • Subject or the subject's legal representative is willing and able to understand and provide signed and dated written prior to screening.

Exclusion criteria

Exclusion Criteria:

  • Women who are breastfeeding.
  • Any evidence of an active Centers for Disease Control and Prevention (CDC) Category C disease Exceptions include cutaneous Kaposi's sarcoma not requiring systemic therapy and historic or current CD4+ cell levels \<200 cells per cubic millimeter
  • Subjects with severe hepatic impairment (Class C) as determined by classification
  • Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, or persistent jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • Anticipated need for virus (HCV) therapy during the Randomized Phase of the study.
  • History or presence of allergy or intolerance to the study drugs or their components or drugs of their class.
  • Ongoing other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia; other localized malignancies require agreement between the investigator and the Study medical monitor for inclusion of the subject.
  • Subjects who in the investigator's judgment, poses a significant suicidality risk. Recent history of suicidal behavior and/or suicidal ideation may be considered as evidence of serious suicide risk.
  • Treatment with an -1 immunotherapeutic vaccine within 90 days of Screening.
  • Treatment with any of the following agents within 28 days of Screening: radiation therapy, cytotoxic chemotherapeutic agents, systemically administered immunomodulators.
  • Treatment with any agent, other than licensed ART as allowed above with documented activity against HIV-1 in vitro/vivo within 28 days of first dose of IP. The exception is use of entecavir, in appropriate clinical situations, for treatment of [e.g. prior intolerance to Tenofovir (TDF), viral resistance to lamivudine (3TC) / Emtricitabine (FTC)] after discussion and agreement between the investigator and the medical monitor.
  • Exposure to an experimental drug or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of IP.
  • Any evidence of primary viral resistance to PIs or INIs based on the presence of any major resistance-associated mutation.
  • The subject's virus does not yield results using genotype at Screening (assay data is essential for eligibility determination).
  • Any verified Grade 4 laboratory abnormality, with the exception of Grade 4 triglycerides. A single repeat test is allowed during the Screening period to verify a result.
  • Any acute laboratory abnormality at Screening, which, in the opinion of the Investigator, would preclude the subject's participation in the study of an compound.
  • (ALT) >=5 times the (ULN) or ALT >=3xULN and >=1.5xULN (with >35% direct bilirubin)
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
627 participants (actual)

Study arms

  • Experimental
    DTG arm

    Subjects will receive one oral tablet of 50 mg DTG once daily plus two NRTIs selected by the investigator

    Drug: DTG · Drug: Two NRTIs

  • Active comparator
    LPV/RTV arm

    Subjects will receive four oral tablets of200/50 mg LPV/RTV once daily or two oral tablets of 200/50 mg LPV/RTV twice daily plus two NRTIs selected by the investigator

    Drug: LPV/RTV · Drug: Two NRTIs

Interventions

  • DrugDTG

    DTG is supplied as 50 mg tablets

  • DrugLPV/RTV

    LPV/RTV is supplied as the LPV/RTV oral tablet, which contains 200 mg of LPV and 50 mg of RTV

  • DrugTwo NRTIs

    Investigators will choose a dual NRTI background regimen for each subject . In consultation with the medical monitor, 3TC may be added as a third NRTI to a dual-NRTI background regimen in subjects with chronic HBV infection and evidence of HIV resistance to 3TC

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) <50 Copies Per Milliliter (c/mL) at Week 48

    Percentage of participants with plasma HIV 1 RNA \<50 c/mL at Week 48 using the Food and Drug Administration (FDA) snapshot algorithm was assessed to demonstrate the non-inferior activity of DTG plus 2 NRTI's compared to LPV/RTV plus 2 NRTI's. Analysis was performed on Intent-to-treat exposed (ITT-E) Population, which comprised of all randomized participants who received at least one dose of study medication. Percentage values are rounded off.

    Time frame: Week 48

Secondary outcomes

  1. Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24

    Percentage of participants with plasma HIV 1 RNA \<50 c/mL at Week 24 using the FDA snapshot algorithm was assessed to demonstrate the non-inferior activity of DTG plus 2 NRTI's compared to LPV/RTV plus 2 NRTI's. Percentage values are rounded off.

    Time frame: Week 24

  2. Percentage of Participants With Plasma HIV-1 RNA <400 c/mL at Weeks 24 and 48

    Percentage of participants with plasma HIV 1 RNA \<400 c/mL at Week 24 and 48 using the FDA snapshot algorithm were evaluated. Percentage values are rounded off.

    Time frame: Week 24 and Week 48

  3. Percentage of Participants Without Virologic or Tolerability Failure at Week 24 and Week 48

    Virologic or tolerability failure was defined as treatment-related discontinuation (meeting confirmed virologic withdrawal criteria, treatment-related adverse event, safety stopping criteria, and lack of efficacy). Percentage of participants without virologic failure by Week 24 and Week 48 have been presented. Participants who did not met the protocol defined confirmed virologic withdrawal criteria and are ongoing in the study, or who had discontinued for non-treatment related reasons were censored.

    Time frame: Week 24 and Week 48

  4. Time to Viral Suppression at Week 48

    Viral suppression was defined as HIV-1 RNA \<50 c/mL. Time to viral suppression was analyzed and median and interquartile range has been presented.

    Time frame: Week 48

  5. Change From Baseline in Helper-inducer T-lymphocyte Having Surface Antigen Cluster of Differentiation (CD4+) Cell Count at Weeks 24 and 48

    Blood was collected and CD4+ cell count assessment was carried out at indicated time points to evaluate the immunological activity of DTG compared to LPV/RTV. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1, Pre-dose), Week 24 and Week 48

  6. Number of Participants With Disease Progression-Randomized + Continuation Phase

    Disease progression included HIV-associated conditions, acquired immune deficiency syndrome (AIDS) and death. Number of participants with disease progression to Centers for Disease Control and Prevention (CDC) class C or death have been presented.

    Time frame: Up to Week 348

  7. Number of Participants With Treatment-emergent Genotypic Resistance-Randomized Phase

    Number of participants, who met confirmed virologic withdrawal (CVW) criteria with paired Baseline and time of CVW resistance data with treatment emergent genotypic resistance to Integrase strand transfer inhibitor (INSTI), NRTI, Protease inhibitor (PI) were summarized. Viral Genotypic Population comprised of all participants in the ITT-E population with available On-treatment genotypic resistance data at the time confirmed virologic withdrawal criterion was met during Randomized Phase.

    Time frame: Up to Week 52

  8. Number of Participants With Treatment-emergent Genotypic Resistance-Continuation Phase

    Number of participants, who met confirmed virologic withdrawal criteria with paired Baseline and time of CVW resistance data, with treatment emergent genotypic resistance to Integrase strand transfer inhibitor (INSTI), NRTI, Protease inhibitor (PI) were summarized. Analysis was performed on Viral Genotypic Continuation Population which comprised all participants in the ITT-E- Continuation Population with available on-treatment genotypic resistance data in the Continuation Phase.

    Time frame: Up to Week 295

  9. Number of Participants With Fold Change in Treatment-emergent Phenotypic Resistance From Baseline-Randomized Phase

    Number of participants with fold change in treatment-emergent phenotypic resistance from Baseline to DTG, LPV/RTV was counted to assess the development of viral resistance. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-dose visit value minus Baseline value. Change in grade 0 to \>2 from Baseline is presented. Analysis was performed on viral phenotypic Population, which comprised of all participants in the ITT-E Population with available On-treatment phenotypic resistance data at the time confirmed virologic withdrawal criterion is met during Randomized Phase.

    Time frame: Baseline (Day 1, Pre-dose) and up to Week 52

  10. Number of Participants With Fold Change in Treatment-emergent Phenotypic Resistance From Baseline-Continuation Phase

    Number of participants with fold change in treatment-emergent phenotypic resistance from Baseline to DTG was counted to assess the development of viral resistance. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-dose visit value minus Baseline value. Change in grade 0 to \>2 from Baseline is presented. Analysis was performed on Viral Phenotypic Continuation Population which comprises all participants in the ITT-E- Continuation Population with available on-treatment phenotypic resistance data in the Continuation Phase.

    Time frame: Baseline (Day 1, Pre-dose) and up to Week 295

  11. Number of Participants With Non-serious Adverse Events (AEs) With >=2% Frequency Threshold and Serious Adverse Events (SAEs)-Randomized Phase

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, other situations as per medical or scientific judgment and is associated with liver injury or impaired liver function. Safety Population was used which comprised of all participants who received at least one dose of study treatment. Adverse events which were not Serious were considered as Non-Serious adverse events.

    Time frame: Up to Week 52

  12. Number of Participants With Non-serious AEs With >=2% Frequency Threshold and SAEs-Continuation Phase

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, other situations as per medical or scientific judgment and is associated with liver injury or impaired liver function. Adverse events which were not Serious were considered as non-serious AEs.

    Time frame: Up to Week 295

  13. Number of Participants With Non-serious AEs With >=2% Frequency Threshold and SAEs-Randomized + Continuation Phase

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, other situations as per medical or scientific judgment and is associated with liver injury or impaired liver function. Adverse events which were not Serious were considered as non-serious AEs.

    Time frame: Up to Week 348

  14. Change From Baseline in Glucose, Chloride, Carbon-di-oxide (CO2), Potassium, Phosphate, Sodium, Urea, Cholesterol, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol and Triglycerides

    Blood samples were collected from participants to evaluate clinical chemistry parameters including glucose, chloride, carbon-di-oxide (CO2), potassium, phosphate, sodium, urea, cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol and triglycerides. Lipid parameters were evaluated in fasting condition. Change from Baseline in clinical chemistry parameters at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.

    Time frame: Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and Week 52

  15. Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatine Kinase Values

    Blood samples were collected from participants to evaluate clinical chemistry parameters including ALP, ALT, AST and creatine kinase. Change from Baseline in clinical chemistry parameters at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.

    Time frame: Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and Week 52

  16. Change From Baseline in Albumin Values

    Blood samples were collected from participants to evaluate clinical chemistry parameter including albumin. Change from Baseline in clinical chemistry parameters at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.

    Time frame: Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and Week 52

  17. Change From Baseline in Creatinine and Bilirubin Values

    Blood samples were collected from participants to evaluate clinical chemistry parameters including creatinine and bilirubin. Change from Baseline in clinical chemistry parameters at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.

    Time frame: Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and Week 52

  18. Change From Baseline in Lipase Values

    Blood samples were collected from participants to evaluate clinical chemistry parameter including lipase. Change from Baseline in lipase at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.

    Time frame: Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and Week 52

  19. Number of Participants With Clinical Chemistry Toxicities -Randomized Phase

    Number of participants with clinical chemistry toxicities has been presented. Toxicities were based on the Division of AIDS (DAIDS) grading system. Grade 1=Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Potentially life-threatening. Higher the grade, more severe the symptoms. Lipids and glucose parameters were summarized on fasting data. Data has been reported for clinical chemistry parameters including serum glucose, ALT, Albumin, ALP, AST, Bilirubin, CO2, Creatine kinase, LDL cholesterol calculation, LDL cholesterol direct, Lipase, Phosphate, Potassium, Sodium, Cholesterol, Creatinine and Serum Triglycerides.

    Time frame: Up to Week 52

  20. Number of Participants With Clinical Chemistry Toxicities-Continuation Phase

    Number of participants with clinical chemistry toxicities has been presented. Toxicities were based on the Division of AIDS (DAIDS) grading system. Grade 1=Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Potentially life-threatening. Higher the grade, more severe the symptoms. Lipids and glucose parameters were summarized on fasting data. Data has been reported for clinical chemistry parameters including serum glucose, ALT, Albumin, ALP, AST, Bilirubin, CO2, Creatine kinase, LDL cholesterol calculation, LDL cholesterol direct, Lipase, Phosphate, Potassium, Sodium, Cholesterol, Creatinine and Serum Triglycerides.

    Time frame: Up to Week 295

  21. Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes

    Blood samples were collected from participants to evaluate clinical hematology parameters including basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes. Change from Baseline in clinical hematology parameters at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.

    Time frame: Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and Week 52

  22. Change From Baseline in Hematocrit Values

    Blood samples were collected from participants to evaluate clinical hematology parameter including hematocrit. Change from Baseline in hematocrit values at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.

    Time frame: Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and and Week 52

  23. Change From Baseline in Hemoglobin Values

    Blood samples were collected from participants to evaluate clinical hematology parameter including hemoglobin. Change from Baseline in hemoglobin values at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.

    Time frame: Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and Week 52

  24. Change From Baseline in Mean Corpuscular Volume (MCV)

    Blood samples were collected from participants to evaluate clinical hematology parameter including MCV. Change from Baseline in MCV values at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.

    Time frame: Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and and Week 52

  25. Change From Baseline in Erythrocyte Values

    Blood samples were collected from participants to evaluate clinical hematology parameter including erythrocyte. Change from Baseline in erythrocyte values at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.

    Time frame: Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and up to Week 52

  26. Number of Participants With Hematology Toxicities -Randomized Phase

    Number of participants with hematology toxicities has been presented. Toxicities were based on the Division of AIDS (DAIDS) grading system. Grade 1=Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Potentially life-threatening. Higher the grade, more severe the symptoms. Data has been reported for hematology parameters including Hemoglobin, Leukocytes, Neutrophils and Platelets.

    Time frame: Up to Week 52

  27. Number of Participants With Hematology Toxicities-Continuation Phase

    Number of participants with hematology toxicities has been presented. Toxicities were based on the Division of AIDS (DAIDS) grading system. Grade 1=Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Potentially life-threatening. Higher the grade, more severe the symptoms. Data has been reported for hematology parameters including Hemoglobin, Leukocytes, Neutrophils and Platelets.

    Time frame: Up to Week 295

  28. Number of Participants Who Discontinued Treatment Due to AEs-Randomized Phase

    Number of participants who discontinued study treatment due to AEs or SAEs were summarized.

    Time frame: Up to Week 52

  29. Number of Participants Who Discontinued Treatment Due to AEs-Continuation Phase

    Number of participants who discontinued study treatment due to AEs were summarized.

    Time frame: Up to Week 295

  30. Change From Baseline in Fasting LDL Cholesterol at Week 24 and Week 48

    Blood samples were collected from participants in fasting state to evaluate LDL cholesterol. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. Analysis was performed using multiple imputation with missing at random assumption. Only participants available at the time of evaluation were analyzed.

    Time frame: Baseline (Day 1, Pre-dose), Week 24 and Week 48

  31. Change From Baseline in Fasting Total Cholesterol/HDL Cholesterol Ratio

    Blood samples were collected from participants in fasting state to evaluate total cholesterol/HDL cholesterol ratio. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. Only participants available at the time of evaluation were analyzed. Analysis was performed using multiple imputation with missing at random assumption.

    Time frame: Baseline (Day 1, Pre-dose), Week 24 and Week 48

  32. Number of Participants With Maximum Post-Baseline Emergent Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol

    Blood samples were collected from participants in fasting state at indicated time-points to evaluate LDL cholesterol. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. Number of participants who experienced maximum grade 2 or greater toxicity post-Baseline in fasting LDL cholesterol was summarized. Participants were graded using the Division of AIDS Table for Grading Severity of Adult and Pediatric Adverse Events. Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=potentially life-threatening. Higher the grade, more severe the symptoms.

    Time frame: Up to Week 48

  33. Number of Participants With Maximum Post-Baseline Emergent Grade 2 or Greater Drug-related Diarrhea

    Number of participants who experienced maximum grade 2 or greater toxicity post-Baseline in drug-related diarrhea was summarized. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. Participants were graded using the Division of AIDS Table for Grading Severity of Adult and Pediatric Adverse Events. Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=potentially life-threatening. Higher the grade, more severe the symptoms.

    Time frame: Week 24 and Week 48

  34. Change From Baseline in Gastrointestinal Symptom Rating Scale (GSRS) Score

    The GSRS is a disease-specific instrument of 15 items combined into five symptom clusters depicting Reflux, Abdominal pain, Indigestion, Diarrhea and Constipation. The scale ranges from 1= no discomfort to 7= very severe discomfort for each symptom cluster. Higher scores show greater severity of symptoms. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. The analysis was performed using Last Observation Carried Forward (LOCF) dataset. In the LOCF dataset, missing values were carried forward from the previous, non-missing available on-treatment assessment.

    Time frame: Baseline (Day 1, Pre-dose), Week 4, Week 24, Week 48

  35. Change From Baseline in Treatment Satisfaction, Using the HIV-Treatment Satisfaction Questionnaire (HIVTSQ) Score

    The HIVTSQ is a self-reported scales that measure overall satisfaction with treatment. The score ranges from 0-10. The higher the score, the greater the improvement in treatment satisfaction as compared to the past few weeks. A smaller score represents a decline in treatment satisfaction compared to the past few weeks. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. The analysis was performed using LOCF dataset. In the LOCF dataset, missing values were carried forward from the previous, non-missing available on-treatment assessment.

    Time frame: Baseline (Day 1, Pre-dose), Week 4, Week 24, Week 48

  36. Number of Participants Showing Adherence With Treatment, Using the Morisky 8-Item Medication Adherence Scale (MMAS-8)

    Treatment compliance was evaluated through MMAS-8. It is an eight-item self-reported measure of medication-taking behavior. The score ranges from 0-8 where scores of 8 indicate high or near perfect adherence, and scores of less than 6 indicate poor or inadequate adherence on the MMAS-8 scale. Number of participants showing low, medium and high adherence to treatment are presented. Low adherence is a score 0-5.75, medium adherence is a score of 6-7.75 and high adherence is a score of 8. The analysis was performed using LOCF dataset. In the LOCF dataset, missing values were carried forward from the previous, non-missing available on-treatment assessment.

    Time frame: Baseline (Day 1, Pre-dose), Week 4, Week 24 and Week 48

07

Results

Posted Jul 12, 2019

Participant flow

This study assessed antiviral activity and safety of dolutegravir (DTG) in human immunodeficiency virus-1 (HIV-1) infected participants with treatment failure on first line therapy. The study consisted of Randomized Phase followed by Continuation Phase.

Randomized Phase (Up to Week 52)
Participant flow — Randomized Phase (Up to Week 52)
MilestoneParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized PhaseParticipants Receiving DTG-Continuation Phase
Started3123150
Itt-e population3123120
Completed2752450
Not completed37700
Withdrew: Reached stopping criteria010
Withdrew: Adverse event8180
Withdrew: Lack of efficacy10220
Withdrew: Protocol violation780
Withdrew: Withdrawal by subject540
Withdrew: Physician decision090
Withdrew: Lost to follow-up750
Withdrew: Randomized, but did not receive treatment030
Continuation Phase(From Weeks 52 to 295)
Participant flow — Continuation Phase(From Weeks 52 to 295)
MilestoneParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized PhaseParticipants Receiving DTG-Continuation Phase
Started00274
Completed00225
Not completed0049
Withdrew: Adverse event008
Withdrew: Lack of efficacy0016
Withdrew: Protocol violation008
Withdrew: Withdrawal by subject006
Withdrew: Physician decision004
Withdrew: Lost to follow-up007

Outcome measures

PrimaryPercentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) <50 Copies Per Milliliter (c/mL) at Week 48

Percentage of participants with plasma HIV 1 RNA \<50 c/mL at Week 48 using the Food and Drug Administration (FDA) snapshot algorithm was assessed to demonstrate the non-inferior activity of DTG plus 2 NRTI's compared to LPV/RTV plus 2 NRTI's. Analysis was performed on Intent-to-treat exposed (ITT-E) Population, which comprised of all randomized participants who received at least one dose of study medication. Percentage values are rounded off.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) <50 Copies Per Milliliter (c/mL) at Week 48
Percentage of participantsParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) <50 Copies Per Milliliter (c/mL) at Week 488470
Statistical analysis
  • Participants Receiving DTG-Randomized Phase vs Participants Receiving LPV/RTV-Randomized Phase · Cochran-Mantel-Haenszel · p = <.001 · Proportion difference: 13.8 · 95% CI 7.3 to 20.3Adjusted proportion difference, calculated as proportion on DTG minus that on LPV/RTV and based on Cochran-Mantel Haenszel stratified analysis adjusting for Baseline plasma HIV-1 RNA and number of fully active background NRTIs, has been presented.
SecondaryPercentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24

Percentage of participants with plasma HIV 1 RNA \<50 c/mL at Week 24 using the FDA snapshot algorithm was assessed to demonstrate the non-inferior activity of DTG plus 2 NRTI's compared to LPV/RTV plus 2 NRTI's. Percentage values are rounded off.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24
Percentage of participantsParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 248269
SecondaryPercentage of Participants With Plasma HIV-1 RNA <400 c/mL at Weeks 24 and 48

Percentage of participants with plasma HIV 1 RNA \<400 c/mL at Week 24 and 48 using the FDA snapshot algorithm were evaluated. Percentage values are rounded off.

Time frame:
Week 24 and Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma HIV-1 RNA <400 c/mL at Weeks 24 and 48
Percentage of participantsParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
Week 249084
Week 488877
SecondaryPercentage of Participants Without Virologic or Tolerability Failure at Week 24 and Week 48

Virologic or tolerability failure was defined as treatment-related discontinuation (meeting confirmed virologic withdrawal criteria, treatment-related adverse event, safety stopping criteria, and lack of efficacy). Percentage of participants without virologic failure by Week 24 and Week 48 have been presented. Participants who did not met the protocol defined confirmed virologic withdrawal criteria and are ongoing in the study, or who had discontinued for non-treatment related reasons were censored.

Time frame:
Week 24 and Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants Without Virologic or Tolerability Failure at Week 24 and Week 48
Percentage of participantsParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
Week 2497.691.9
Week 4896.086.1
Statistical analysis
  • Participants Receiving DTG-Randomized Phase vs Participants Receiving LPV/RTV-Randomized Phase · Proportion difference: 5.7 · 95% CI 2.2 to 9.3Proportion difference, calculated as proportion on DTG minus proportion on LPV/RTV, at Week 24 has been presented.
  • Participants Receiving DTG-Randomized Phase vs Participants Receiving LPV/RTV-Randomized Phase · Proportion difference: 9.8 · 95% CI 5.3 to 14.4Proportion difference, calculated as proportion on DTG minus proportion on LPV/RTV, at Week 48 has been presented.
SecondaryTime to Viral Suppression at Week 48

Viral suppression was defined as HIV-1 RNA \<50 c/mL. Time to viral suppression was analyzed and median and interquartile range has been presented.

Time frame:
Week 48
Reported as:
Median · Days
Time to Viral Suppression at Week 48
DaysParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
Time to Viral Suppression at Week 4829.0 (29.0 to 57.0)111.0 (35.0 to 167.0)
SecondaryChange From Baseline in Helper-inducer T-lymphocyte Having Surface Antigen Cluster of Differentiation (CD4+) Cell Count at Weeks 24 and 48

Blood was collected and CD4+ cell count assessment was carried out at indicated time points to evaluate the immunological activity of DTG compared to LPV/RTV. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1, Pre-dose), Week 24 and Week 48
Reported as:
Median · Cells per cubic millimeter (Cells/mm^3)
Change From Baseline in Helper-inducer T-lymphocyte Having Surface Antigen Cluster of Differentiation (CD4+) Cell Count at Weeks 24 and 48
Cells per cubic millimeter (Cells/mm^3)Participants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
Week 24; n= 291, 28584.0 (31.0 to 146.0)82.0 (31.0 to 146.0)
Week 48; n= 275, 251120.0 (63.0 to 204.0)118.0 (66.0 to 191.0)
SecondaryNumber of Participants With Disease Progression-Randomized + Continuation Phase

Disease progression included HIV-associated conditions, acquired immune deficiency syndrome (AIDS) and death. Number of participants with disease progression to Centers for Disease Control and Prevention (CDC) class C or death have been presented.

Time frame:
Up to Week 348
Reported as:
Count of participants · Participants
Number of Participants With Disease Progression-Randomized + Continuation Phase
ParticipantsDTG in Randomized Phase Followed by Continuation PhaseLPV/RTV-Randomized Phase Followed by DTG in Continuation Phase
Number of Participants With Disease Progression-Randomized + Continuation Phase107
SecondaryNumber of Participants With Treatment-emergent Genotypic Resistance-Randomized Phase

Number of participants, who met confirmed virologic withdrawal (CVW) criteria with paired Baseline and time of CVW resistance data with treatment emergent genotypic resistance to Integrase strand transfer inhibitor (INSTI), NRTI, Protease inhibitor (PI) were summarized. Viral Genotypic Population comprised of all participants in the ITT-E population with available On-treatment genotypic resistance data at the time confirmed virologic withdrawal criterion was met during Randomized Phase.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Genotypic Resistance-Randomized Phase
ParticipantsParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
INSTI30
NRTI13
PI00
SecondaryNumber of Participants With Treatment-emergent Genotypic Resistance-Continuation Phase

Number of participants, who met confirmed virologic withdrawal criteria with paired Baseline and time of CVW resistance data, with treatment emergent genotypic resistance to Integrase strand transfer inhibitor (INSTI), NRTI, Protease inhibitor (PI) were summarized. Analysis was performed on Viral Genotypic Continuation Population which comprised all participants in the ITT-E- Continuation Population with available on-treatment genotypic resistance data in the Continuation Phase.

Time frame:
Up to Week 295
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Genotypic Resistance-Continuation Phase
ParticipantsParticipants Receiving DTG-Continuation Phase
INSTI5
NRTI2
PI0
SecondaryNumber of Participants With Fold Change in Treatment-emergent Phenotypic Resistance From Baseline-Randomized Phase

Number of participants with fold change in treatment-emergent phenotypic resistance from Baseline to DTG, LPV/RTV was counted to assess the development of viral resistance. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-dose visit value minus Baseline value. Change in grade 0 to \>2 from Baseline is presented. Analysis was performed on viral phenotypic Population, which comprised of all participants in the ITT-E Population with available On-treatment phenotypic resistance data at the time confirmed virologic withdrawal criterion is met during Randomized Phase.

Time frame:
Baseline (Day 1, Pre-dose) and up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Fold Change in Treatment-emergent Phenotypic Resistance From Baseline-Randomized Phase
ParticipantsParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
DTG; <1; n=11, 23518
DTG; 1-<2; n=11, 2325
DTG; 2-<4; n=11, 2310
DTG; 4-<8; n=11, 2300
DTG; >=8; n=11, 2330
LPV/RTV; <1; n=11, 29721
LPV/RTV; 1-<2; n=11, 2948
LPV/RTV; 2-<4; n=11, 2900
LPV/RTV; 4-<8; n=11, 2900
LPV/RTV; >=8; n=11, 2900
SecondaryNumber of Participants With Fold Change in Treatment-emergent Phenotypic Resistance From Baseline-Continuation Phase

Number of participants with fold change in treatment-emergent phenotypic resistance from Baseline to DTG was counted to assess the development of viral resistance. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-dose visit value minus Baseline value. Change in grade 0 to \>2 from Baseline is presented. Analysis was performed on Viral Phenotypic Continuation Population which comprises all participants in the ITT-E- Continuation Population with available on-treatment phenotypic resistance data in the Continuation Phase.

Time frame:
Baseline (Day 1, Pre-dose) and up to Week 295
Reported as:
Count of participants · Participants
Number of Participants With Fold Change in Treatment-emergent Phenotypic Resistance From Baseline-Continuation Phase
ParticipantsParticipants Receiving DTG in Continuation Phase
DTG; <18
DTG; 1-<23
DTG; 2-<40
DTG; 4-<80
DTG; >=84
SecondaryNumber of Participants With Non-serious Adverse Events (AEs) With >=2% Frequency Threshold and Serious Adverse Events (SAEs)-Randomized Phase

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, other situations as per medical or scientific judgment and is associated with liver injury or impaired liver function. Safety Population was used which comprised of all participants who received at least one dose of study treatment. Adverse events which were not Serious were considered as Non-Serious adverse events.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Non-serious Adverse Events (AEs) With >=2% Frequency Threshold and Serious Adverse Events (SAEs)-Randomized Phase
ParticipantsParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
Any non-serious AEs155202
Any SAEs2020
SecondaryNumber of Participants With Non-serious AEs With >=2% Frequency Threshold and SAEs-Continuation Phase

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, other situations as per medical or scientific judgment and is associated with liver injury or impaired liver function. Adverse events which were not Serious were considered as non-serious AEs.

Time frame:
Up to Week 295
Reported as:
Count of participants · Participants
Number of Participants With Non-serious AEs With >=2% Frequency Threshold and SAEs-Continuation Phase
ParticipantsParticipants Receiving DTG-Continuation Phase
Any non-serious AEs150
Any SAEs29
SecondaryNumber of Participants With Non-serious AEs With >=2% Frequency Threshold and SAEs-Randomized + Continuation Phase

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, other situations as per medical or scientific judgment and is associated with liver injury or impaired liver function. Adverse events which were not Serious were considered as non-serious AEs.

Time frame:
Up to Week 348
Reported as:
Count of participants · Participants
Number of Participants With Non-serious AEs With >=2% Frequency Threshold and SAEs-Randomized + Continuation Phase
ParticipantsDTG- Randomized Phase Followed by Continuation PhaseLPV/RTV- Randomized Phase Followed by DTG-Continuation Phase
Any non-serious AEs218213
Any SAEs4720
SecondaryChange From Baseline in Glucose, Chloride, Carbon-di-oxide (CO2), Potassium, Phosphate, Sodium, Urea, Cholesterol, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol and Triglycerides

Blood samples were collected from participants to evaluate clinical chemistry parameters including glucose, chloride, carbon-di-oxide (CO2), potassium, phosphate, sodium, urea, cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol and triglycerides. Lipid parameters were evaluated in fasting condition. Change from Baseline in clinical chemistry parameters at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.

Time frame:
Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and Week 52
Reported as:
Mean · Millimoles per liter
Change From Baseline in Glucose, Chloride, Carbon-di-oxide (CO2), Potassium, Phosphate, Sodium, Urea, Cholesterol, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol and Triglycerides
Millimoles per literParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
Glucose; Week 4; n= 279, 2770.07 ± 0.7890.01 ± 0.661
Glucose; Week 8; n= 273, 2710.08 ± 1.086-0.00 ± 0.914
Glucose; Week 16; n= 280, 2750.07 ± 0.740-0.06 ± 1.060
Glucose; Week 24; n= 288, 2760.22 ± 2.286-0.04 ± 1.037
Glucose; Week 36; n= 270, 2570.18 ± 1.056-0.01 ± 1.176
Glucose; Week 48; n= 269, 2370.12 ± 1.099-0.01 ± 1.028
Glucose; Week 52; n= 258, 2210.16 ± 1.142-0.01 ± 1.443
Chloride; Week 4; n= 306, 302-0.20 ± 2.692-0.96 ± 2.751
Chloride; Week 8; n= 301, 298-0.15 ± 2.752-1.00 ± 2.833
Chloride; Week 16; n= 294, 2920.04 ± 2.709-0.78 ± 2.773
Chloride; Week 24; n= 295, 286-0.17 ± 2.887-0.67 ± 2.818
Chloride; Week 36; n= 289, 276-0.18 ± 2.569-0.51 ± 2.880
Chloride; Week 48; n= 278, 247-0.03 ± 2.663-0.81 ± 2.441
Chloride; Week 52; n= 276, 2380.06 ± 3.111-0.38 ± 2.739
CO2; Week 4; n= 306, 3020.12 ± 2.754-0.22 ± 2.650
CO2; Week 8; n= 301, 297-0.01 ± 2.695-0.09 ± 2.564
CO2; Week 16; n= 294, 2920.21 ± 2.9780.04 ± 2.638
CO2; Week 24; n= 295, 2860.13 ± 2.818-0.08 ± 2.777
CO2; Week 36; n= 289, 2760.16 ± 2.620-0.12 ± 2.861
CO2; Week 48; n= 278, 2470.06 ± 2.6720.28 ± 2.867
CO2; Week 52; n= 276, 2380.04 ± 2.7360.12 ± 2.555
Potassium; Week 4; n= 306, 3020.07 ± 0.373-0.02 ± 0.432
Potassium; Week 8; n= 301, 2970.09 ± 0.3500.00 ± 0.428
Potassium; Week 16; n= 294, 2920.10 ± 0.3750.03 ± 0.443
Potassium; Week 24; n= 295, 2860.11 ± 0.4010.03 ± 0.433
Potassium; Week 36; n= 289, 2760.08 ± 0.363-0.03 ± 0.417
Potassium; Week 48; n= 278, 2470.07 ± 0.3690.05 ± 0.423
Potassium; Week 52; n= 276, 2380.11 ± 0.4120.04 ± 0.416
Phosphate; Week 4; n= 306, 3020.11 ± 0.1880.01 ± 0.206
Phosphate; Week 8; n= 301, 2980.11 ± 0.1820.03 ± 0.187
Phosphate; Week 16; n= 294, 2920.10 ± 0.1800.03 ± 0.193
Phosphate; Week 24; n= 295, 2860.11 ± 0.1740.03 ± 0.200
Phosphate; Week 36; n= 289, 2760.08 ± 0.1960.01 ± 0.217
Phosphate; Week 48; n= 278, 2470.06 ± 0.1930.03 ± 0.209
Phosphate; Week 52; n= 276, 2380.06 ± 0.2030.01 ± 0.197
Sodium; Week 4; n= 306, 302-0.20 ± 2.393-0.80 ± 2.284
Sodium; Week 8; n= 301, 298-0.12 ± 2.420-0.87 ± 2.569
Sodium; Week 16; n= 294, 2920.29 ± 2.364-0.58 ± 2.449
Sodium; Week 24; n= 295, 286-0.07 ± 2.472-0.53 ± 2.446
Sodium; Week 36; n= 289, 2760.08 ± 2.375-0.51 ± 2.410
Sodium; Week 48; n= 278, 2470.22 ± 2.277-0.62 ± 2.505
Sodium; Week 52; n= 276, 2380.09 ± 2.886-0.37 ± 2.402
Urea; Week 4; n= 306, 3020.21 ± 1.6580.18 ± 1.253
Urea; Week 8; n= 301, 2980.21 ± 1.2140.23 ± 1.205
Urea; Week 16; n= 294, 2920.25 ± 1.2690.29 ± 1.344
Urea; Week 24; n= 295, 2860.35 ± 1.2360.17 ± 1.308
Urea; Week 36; n= 289, 2760.11 ± 1.1650.20 ± 1.284
Urea; Week 48; n= 278, 2470.19 ± 1.2600.18 ± 1.241
Urea; Week 52; n= 276, 2380.30 ± 1.4820.32 ± 1.311
Cholesterol; Week 4; n= 4, 6-0.88 ± 1.0811.22 ± 1.963
Cholesterol; Week 8; n= 7, 10-0.37 ± 1.1581.04 ± 1.577
Cholesterol; Week 16; n= 270, 261-0.22 ± 0.8780.31 ± 0.872
Cholesterol; Week 24; n= 280, 271-0.23 ± 0.7600.29 ± 0.934
Cholesterol; Week 36; n= 283, 272-0.24 ± 0.7890.28 ± 0.901
Cholesterol; Week 48; n= 276, 272-0.10 ± 0.8080.38 ± 0.946
Cholesterol; Week 52; n= 7, 60.35 ± 0.593-0.18 ± 0.850
HDL cholesterol; Week 4; n= 4, 6-0.18 ± 0.1970.10 ± 0.191
HDL cholesterol; Week 8; n= 7,10-0.01 ± 0.2620.08 ± 0.363
HDL cholesterol; Week 16; n= 270, 261-0.02 ± 0.300-0.00 ± 0.341
HDL cholesterol; Week 24; n= 280, 271-0.02 ± 0.3190.00 ± 0.339
HDL cholesterol; Week 36; n= 283, 272-0.02 ± 0.3190.00 ± 0.340
HDL cholesterol; Week 48; n= 276, 272-0.02 ± 0.2980.03 ± 0.353
HDL cholesterol; Week 52; n= 7,60.18 ± 0.3270.13 ± 0.327
LDL cholesterol; Week 4; n= 4, 3-0.29 ± 1.157-0.17 ± 0.398
LDL cholesterol; Week 8; n= 7, 8-0.09 ± 0.9110.50 ± 0.720
LDL cholesterol; Week 16; n= 259, 246-0.10 ± 0.6740.06 ± 0.644
LDL cholesterol; Week 24; n= 272, 261-0.10 ± 0.6010.05 ± 0.652
LDL cholesterol; Week 36; n= 274, 261-0.11 ± 0.6060.05 ± 0.659
LDL cholesterol; Week 48; n= 269, 264-0.01 ± 0.6330.11 ± 0.682
LDL cholesterol; Week 52; n= 7, 60.06 ± 0.511-0.25 ± 0.857
Triglycerides; Week 4; n= 4, 6-0.89 ± 0.8524.23 ± 5.773
Triglycerides; Week 8; n= 7, 10-0.57 ± 1.1531.95 ± 5.131
Triglycerides; Week 16; n= 270, 261-0.32 ± 1.1310.63 ± 1.289
Triglycerides; Week 24; n= 280, 271-0.32 ± 0.9970.67 ± 1.826
Triglycerides; Week 36; n= 283, 272-0.31 ± 1.2890.61 ± 1.497
Triglycerides; Week 48; n= 276, 272-0.24 ± 1.1200.57 ± 1.488
Triglycerides; Week 52; n= 7, 60.22 ± 0.769-0.15 ± 0.259
SecondaryChange From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatine Kinase Values

Blood samples were collected from participants to evaluate clinical chemistry parameters including ALP, ALT, AST and creatine kinase. Change from Baseline in clinical chemistry parameters at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.

Time frame:
Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and Week 52
Reported as:
Mean · International unit per liter
Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatine Kinase Values
International unit per literParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
ALP; Week 4; n= 306, 302-12.24 ± 21.900-14.94 ± 22.979
ALP; Week 8; n= 301, 298-13.73 ± 26.135-13.46 ± 29.998
ALP; Week 16; n= 294, 292-13.87 ± 31.452-11.38 ± 26.190
ALP; Week 24; n= 295, 286-14.19 ± 27.800-6.06 ± 50.943
ALP; Week 36; n= 289, 276-13.53 ± 28.875-7.85 ± 30.394
ALP; Week 48; n= 278, 247-14.10 ± 28.935-6.87 ± 32.071
ALP; Week 52; n= 276, 238-13.81 ± 29.317-7.23 ± 31.046
ALT; Week 4; n= 306, 302-2.50 ± 17.285-10.25 ± 17.639
ALT; Week 8; n= 301, 298-2.49 ± 19.222-9.04 ± 25.556
ALT; Week 16; n= 294, 292-4.32 ± 18.502-8.59 ± 24.507
ALT; Week 24; n= 295, 286-3.87 ± 20.108-9.20 ± 33.054
ALT; Week 36; n= 289, 276-1.31 ± 25.356-11.16 ± 22.196
ALT; Week 48; n= 278, 2470.19 ± 39.985-6.47 ± 51.492
ALT; Week 52; n= 276, 238-1.04 ± 23.232-10.63 ± 25.508
AST; Week 4; n= 306, 302-3.56 ± 17.463-7.68 ± 13.654
AST; Week 8; n= 301, 297-2.89 ± 17.934-6.64 ± 21.295
AST; Week 16; n= 294, 292-4.70 ± 17.445-6.49 ± 18.143
AST; Week 24; n= 295, 286-3.83 ± 17.713-6.45 ± 28.933
AST; Week 36; n= 289, 276-1.76 ± 22.437-8.36 ± 21.550
AST; Week 48; n= 278, 247-2.03 ± 28.194-6.43 ± 27.155
AST; Week 52; n= 276, 238-1.51 ± 22.645-7.55 ± 28.125
Creatine kinase; Week 4; n= 306, 302-2.85 ± 215.820-15.59 ± 106.738
Creatine kinase; Week 8; n= 301, 29818.61 ± 312.940-10.42 ± 128.109
Creatine kinase; Week 16; n= 294, 29211.75 ± 180.90511.62 ± 203.660
Creatine kinase; Week 24; n= 295, 28634.71 ± 312.173-0.28 ± 186.927
Creatine kinase; Week 36; n= 289, 27672.34 ± 892.830-5.08 ± 135.191
Creatine kinase; Week 48; n= 278, 24745.50 ± 451.13516.52 ± 295.891
Creatine kinase; Week 52; n= 276, 23839.24 ± 228.02654.97 ± 628.621
SecondaryChange From Baseline in Albumin Values

Blood samples were collected from participants to evaluate clinical chemistry parameter including albumin. Change from Baseline in clinical chemistry parameters at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.

Time frame:
Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and Week 52
Reported as:
Mean · Gram per liter
Change From Baseline in Albumin Values
Gram per literParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
Week 4; n= 306, 302-0.39 ± 2.554-0.51 ± 2.670
Week 8; n= 301, 2980.09 ± 2.792-0.67 ± 2.828
Week 16; n= 294, 2920.50 ± 3.148-0.28 ± 3.062
Week 24; n= 295, 2860.63 ± 3.326-0.06 ± 3.207
Week 36; n= 289, 2760.76 ± 3.479-0.11 ± 3.091
Week 48; n= 278, 2470.71 ± 3.2500.11 ± 2.912
Week 52; n= 276, 2380.83 ± 3.605-0.15 ± 3.142
SecondaryChange From Baseline in Creatinine and Bilirubin Values

Blood samples were collected from participants to evaluate clinical chemistry parameters including creatinine and bilirubin. Change from Baseline in clinical chemistry parameters at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.

Time frame:
Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and Week 52
Reported as:
Mean · Micromoles per liter
Change From Baseline in Creatinine and Bilirubin Values
Micromoles per literParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
Creatinine; Week 4; n= 306, 3029.68 ± 9.3084.69 ± 8.575
Creatinine; Week 8; n= 301, 29810.81 ± 8.4145.57 ± 9.214
Creatinine; Week 16; n= 294, 29212.46 ± 9.0655.19 ± 9.648
Creatinine; Week 24; n= 295, 28612.96 ± 10.2485.75 ± 11.606
Creatinine; Week 36; n= 289, 27612.08 ± 9.6675.98 ± 14.737
Creatinine; Week 48; n= 278, 24712.92 ± 9.4126.15 ± 13.373
Creatinine; Week 52; n= 276, 23813.22 ± 10.2296.15 ± 12.268
Bilirubin; Week 4; n= 305, 3011.74 ± 4.9823.39 ± 3.997
Bilirubin; Week 8; n= 301, 2972.25 ± 4.3443.76 ± 5.291
Bilirubin; Week 16; n= 294, 2922.79 ± 4.5473.97 ± 4.957
Bilirubin; Week 24; n= 295, 2853.28 ± 4.6924.15 ± 5.422
Bilirubin; Week 36; n= 289, 2753.26 ± 4.9254.43 ± 5.447
Bilirubin; Week 48; n= 278, 2463.19 ± 4.2884.82 ± 5.552
Bilirubin; Week 52; n= 276, 2383.54 ± 5.2314.26 ± 4.644
SecondaryChange From Baseline in Lipase Values

Blood samples were collected from participants to evaluate clinical chemistry parameter including lipase. Change from Baseline in lipase at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.

Time frame:
Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and Week 52
Reported as:
Mean · Unit per liter
Change From Baseline in Lipase Values
Unit per literParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
Week 4; n= 303, 3010.17 ± 11.0821.52 ± 15.067
Week 8; n= 299, 2980.79 ± 13.4220.58 ± 10.558
Week 16; n= 292, 2932.01 ± 17.1740.94 ± 11.197
Week 24; n= 295, 2841.19 ± 15.9841.14 ± 13.770
Week 36; n= 287, 2750.49 ± 15.0890.11 ± 11.570
Week 48; n= 278, 2471.13 ± 14.6731.68 ± 12.783
Week 52; n= 275, 2373.18 ± 22.2151.59 ± 11.117
SecondaryNumber of Participants With Clinical Chemistry Toxicities -Randomized Phase

Number of participants with clinical chemistry toxicities has been presented. Toxicities were based on the Division of AIDS (DAIDS) grading system. Grade 1=Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Potentially life-threatening. Higher the grade, more severe the symptoms. Lipids and glucose parameters were summarized on fasting data. Data has been reported for clinical chemistry parameters including serum glucose, ALT, Albumin, ALP, AST, Bilirubin, CO2, Creatine kinase, LDL cholesterol calculation, LDL cholesterol direct, Lipase, Phosphate, Potassium, Sodium, Cholesterol, Creatinine and Serum Triglycerides.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Clinical Chemistry Toxicities -Randomized Phase
ParticipantsParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
Serum glucose; Grade 13227
Serum glucose; Grade 21015
Serum glucose; Grade 341
Serum glucose; Grade 410
ALT; Grade 12713
ALT; Grade 296
ALT; Grade 332
ALT; Grade 410
Albumin; Grade 173
Albumin; Grade 240
Albumin; Grade 300
Albumin; Grade 400
ALP; Grade 1922
ALP; Grade 241
ALP; Grade 301
ALP; Grade 400
AST; Grade 12918
AST; Grade 2104
AST; Grade 325
AST; Grade 410
Bilirubin; Grade 11421
Bilirubin; Grade 2311
Bilirubin; Grade 320
Bilirubin; Grade 400
CO2; Grade 199105
CO2; Grade 22413
CO2; Grade 310
CO2; Grade 400
Creatine kinase; Grade 1136
Creatine kinase; Grade 223
Creatine kinase; Grade 353
Creatine kinase; Grade 431
LDL cholesterol calculation; Grade 11720
LDL cholesterol calculation; Grade 2416
LDL cholesterol calculation; Grade 314
LDL cholesterol calculation; Grade 400
LDL cholesterol direct; Grade 138
LDL cholesterol direct; Grade 224
LDL cholesterol direct; Grade 301
LDL cholesterol direct; Grade 400
Lipase; Grade 11612
Lipase; Grade 265
Lipase; Grade 311
Lipase; Grade 420
Phosphate; Grade 176
Phosphate; Grade 21542
Phosphate; Grade 358
Phosphate; Grade 400
Potassium; Grade 11620
Potassium; Grade 211
Potassium; Grade 323
Potassium; Grade 411
Sodium; Grade 176117
Sodium; Grade 252
Sodium; Grade 310
Sodium; Grade 410
Cholesterol; Grade 11446
Cholesterol; Grade 2532
Cholesterol; Grade 334
Cholesterol; Grade 400
Creatinine; Grade 114
Creatinine; Grade 225
Creatinine; Grade 300
Creatinine; Grade 400
Serum Triglycerides; Grade 100
Serum Triglycerides; Grade 2111
Serum Triglycerides; Grade 313
Serum Triglycerides; Grade 412
SecondaryNumber of Participants With Clinical Chemistry Toxicities-Continuation Phase

Number of participants with clinical chemistry toxicities has been presented. Toxicities were based on the Division of AIDS (DAIDS) grading system. Grade 1=Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Potentially life-threatening. Higher the grade, more severe the symptoms. Lipids and glucose parameters were summarized on fasting data. Data has been reported for clinical chemistry parameters including serum glucose, ALT, Albumin, ALP, AST, Bilirubin, CO2, Creatine kinase, LDL cholesterol calculation, LDL cholesterol direct, Lipase, Phosphate, Potassium, Sodium, Cholesterol, Creatinine and Serum Triglycerides.

Time frame:
Up to Week 295
Reported as:
Count of participants · Participants
Number of Participants With Clinical Chemistry Toxicities-Continuation Phase
ParticipantsParticipants Receiving DTG in Continuation Phase
Serum glucose; Grade 143
Serum glucose; Grade 233
Serum glucose; Grade 39
Serum glucose; Grade 40
ALT; Grade 146
ALT; Grade 216
ALT; Grade 32
ALT; Grade 40
Albumin; Grade 11
Albumin; Grade 24
Albumin; Grade 30
Albumin; Grade 40
ALP; Grade 113
ALP; Grade 22
ALP; Grade 30
ALP; Grade 40
AST; Grade 137
AST; Grade 211
AST; Grade 35
AST; Grade 41
Bilirubin; Grade 114
Bilirubin; Grade 29
Bilirubin; Grade 30
Bilirubin; Grade 42
CO2; Grade 183
CO2; Grade 220
CO2; Grade 30
CO2; Grade 40
Creatine kinase; Grade 124
Creatine kinase; Grade 26
Creatine kinase; Grade 35
Creatine kinase; Grade 45
LDL cholesterol calculation; Grade 11
LDL cholesterol calculation; Grade 21
LDL cholesterol calculation; Grade 30
LDL cholesterol calculation; Grade 40
LDL cholesterol direct; Grade 11
LDL cholesterol direct; Grade 21
LDL cholesterol direct; Grade 30
LDL cholesterol direct; Grade 40
Lipase; Grade 119
Lipase; Grade 29
Lipase; Grade 32
Lipase; Grade 44
Phosphate; Grade 116
Phosphate; Grade 238
Phosphate; Grade 36
Phosphate; Grade 40
Potassium; Grade 124
Potassium; Grade 25
Potassium; Grade 31
Potassium; Grade 41
Sodium; Grade 169
Sodium; Grade 20
Sodium; Grade 30
Sodium; Grade 40
Cholesterol; Grade 11
Cholesterol; Grade 20
Cholesterol; Grade 31
Cholesterol; Grade 40
Creatinine; Grade 17
Creatinine; Grade 24
Creatinine; Grade 30
Creatinine; Grade 40
Serum Triglycerides; Grade 10
Serum Triglycerides; Grade 20
Serum Triglycerides; Grade 30
Serum Triglycerides; Grade 41
SecondaryChange From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes

Blood samples were collected from participants to evaluate clinical hematology parameters including basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes. Change from Baseline in clinical hematology parameters at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.

Time frame:
Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and Week 52
Reported as:
Mean · 10^9 cells/liter
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes
10^9 cells/literParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
Basophil; Week 4; n= 289, 2910.00 ± 0.0290.00 ± 0.016
Basophil; Week 8; n= 296, 2890.00 ± 0.0170.00 ± 0.017
Basophil; Week 16; n= 286, 2860.00 ± 0.0170.00 ± 0.017
Basophil; Week 24; n= 290, 2810.01 ± 0.0170.00 ± 0.017
Basophil; Week 36; n= 283, 2750.01 ± 0.0210.00 ± 0.018
Basophil; Week 48; n= 266, 2420.01 ± 0.0210.01 ± 0.019
Basophil; Week 52; n= 265, 2290.01 ± 0.0180.01 ± 0.022
Eosinophil; Week 4; n= 290, 2910.02 ± 0.1820.02 ± 0.287
Eosinophil; Week 8; n= 296, 2890.03 ± 0.2810.01 ± 0.175
Eosinophil; Week 16; n= 286, 2860.01 ± 0.2400.01 ± 0.201
Eosinophil; Week 24; n= 290, 2810.02 ± 0.1880.01 ± 0.173
Eosinophil; Week 36; n= 283, 2750.04 ± 0.2140.02 ± 0.192
Eosinophil; Week 48; n= 266, 2420.04 ± 0.2670.01 ± 0.210
Eosinophil; Week 52; n= 265, 2290.02 ± 0.1880.01 ± 0.217
Lymphocyte; Week 4; n= 289, 2910.13 ± 0.5190.10 ± 0.549
Lymphocyte; Week 8; n= 296, 2890.23 ± 0.5920.29 ± 0.651
Lymphocyte; Week 16; n= 286, 2860.28 ± 0.6110.29 ± 0.668
Lymphocyte; Week 24; n= 290, 2810.31 ± 0.5890.34 ± 0.625
Lymphocyte; Week 36; n= 283, 2750.38 ± 0.5950.35 ± 0.646
Lymphocyte; Week 48; n= 266, 2420.38 ± 0.6480.37 ± 0.697
Lymphocyte; Week 52; n= 265, 2290.34 ± 0.7160.39 ± 0.720
Monocyte; Week 4; n= 289, 2910.02 ± 0.2010.00 ± 0.167
Monocyte; Week 8; n= 296, 2890.01 ± 0.1590.02 ± 0.174
Monocyte; Week 16; n= 286, 286-0.00 ± 0.1400.01 ± 0.154
Monocyte; Week 24; n= 290, 281-0.01 ± 0.1390.01 ± 0.173
Monocyte; Week 36; n= 283, 2750.01 ± 0.1510.02 ± 0.175
Monocyte; Week 48; n= 266, 2420.01 ± 0.1570.03 ± 0.190
Monocyte; Week 52; n= 265, 2290.01 ± 0.1730.02 ± 0.205
Neutrophil; Week 4; n= 289, 2910.35 ± 1.9140.23 ± 1.407
Neutrophil; Week 8; n= 296, 2890.27 ± 1.4910.23 ± 1.678
Neutrophil; Week 16; n= 286, 2860.31 ± 1.4620.29 ± 1.481
Neutrophil; Week 24; n= 290, 2810.42 ± 1.6940.34 ± 1.315
Neutrophil; Week 36; n= 283, 2750.50 ± 1.6050.37 ± 1.661
Neutrophil; Week 48; n= 266, 2420.46 ± 1.4910.50 ± 1.449
Neutrophil; Week 52; n= 265, 2290.63 ± 1.6910.44 ± 1.604
Platelet; Week 4; n= 291, 29322.81 ± 63.36823.64 ± 53.514
Platelet; Week 8; n= 293, 29322.95 ± 62.96926.17 ± 58.634
Platelet; Week 16; n= 287, 28621.77 ± 66.97428.03 ± 61.780
Platelet; Week 24; n= 290, 28219.79 ± 63.70227.32 ± 65.103
Platelet; Week 36; n= 283, 27420.02 ± 69.57021.41 ± 64.787
Platelet; Week 48; n= 265, 24616.72 ± 66.98330.20 ± 63.038
Platelet; Week 52; n= 267, 23220.98 ± 66.40232.60 ± 71.882
Leukocyte; Week 4; n= 289, 2920.51 ± 2.1050.37 ± 1.607
Leukocyte; Week 8; n= 296, 2920.54 ± 1.6760.54 ± 1.879
Leukocyte; Week 16; n= 290, 2880.61 ± 1.6220.60 ± 1.746
Leukocyte; Week 24; n= 291, 2840.75 ± 1.8260.70 ± 1.545
Leukocyte; Week 36; n= 285, 2760.91 ± 1.7770.76 ± 1.913
Leukocyte; Week 48; n= 267, 2450.91 ± 1.7770.90 ± 1.718
Leukocyte; Week 52; 268, 2310.99 ± 1.9080.86 ± 1.819
SecondaryChange From Baseline in Hematocrit Values

Blood samples were collected from participants to evaluate clinical hematology parameter including hematocrit. Change from Baseline in hematocrit values at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.

Time frame:
Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and and Week 52
Reported as:
Mean · Proportion of red blood cells in blood
Change From Baseline in Hematocrit Values
Proportion of red blood cells in bloodParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
Week 4; n= 296, 296-0.00 ± 0.032-0.01 ± 0.029
Week 8; n= 297, 2940.00 ± 0.039-0.01 ± 0.037
Week 16; n= 290, 2890.01 ± 0.044-0.01 ± 0.042
Week 24; n= 291, 2850.01 ± 0.037-0.00 ± 0.039
Week 36; n= 286, 2760.01 ± 0.038-0.00 ± 0.039
Week 48; n= 268, 2480.02 ± 0.038-0.00 ± 0.041
Week 52; n= 269, 2330.02 ± 0.040-0.00 ± 0.041
SecondaryChange From Baseline in Hemoglobin Values

Blood samples were collected from participants to evaluate clinical hematology parameter including hemoglobin. Change from Baseline in hemoglobin values at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.

Time frame:
Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and Week 52
Reported as:
Mean · Gram per liter
Change From Baseline in Hemoglobin Values
Gram per literParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
Week 4; n= 296, 296-1.33 ± 9.858-4.23 ± 8.994
Week 8; n= 297, 294-0.12 ± 11.725-4.41 ± 11.340
Week 16; n= 290, 2892.39 ± 12.905-2.10 ± 12.904
Week 24; n= 291, 2853.05 ± 10.881-0.46 ± 12.363
Week 36; n= 286, 2765.18 ± 11.9680.34 ± 12.628
Week 48; n= 268, 2486.05 ± 12.1380.90 ± 13.486
Week 52; n= 269, 2335.68 ± 12.4571.07 ± 13.361
SecondaryChange From Baseline in Mean Corpuscular Volume (MCV)

Blood samples were collected from participants to evaluate clinical hematology parameter including MCV. Change from Baseline in MCV values at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.

Time frame:
Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and and Week 52
Reported as:
Mean · Femtoliter
Change From Baseline in Mean Corpuscular Volume (MCV)
FemtoliterParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
Week 4; n= 296, 2960.68 ± 3.8200.46 ± 3.799
Week 8; n= 297, 2941.72 ± 7.6591.78 ± 7.266
Week 16; n= 290, 2893.91 ± 13.8273.83 ± 13.600
Week 24; n= 291, 2854.86 ± 15.2794.39 ± 15.099
Week 36; n= 286, 2764.33 ± 15.4504.62 ± 15.413
Week 48; n= 268, 2484.14 ± 15.6374.79 ± 15.463
Week 52; n= 269, 2334.36 ± 15.4964.72 ± 15.697
SecondaryChange From Baseline in Erythrocyte Values

Blood samples were collected from participants to evaluate clinical hematology parameter including erythrocyte. Change from Baseline in erythrocyte values at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.

Time frame:
Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and up to Week 52
Reported as:
Mean · 10^12 cells/liter
Change From Baseline in Erythrocyte Values
10^12 cells/literParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
Week 4; n= 296, 296-0.08 ± 0.385-0.16 ± 0.363
Week 8; n= 297, 294-0.07 ± 0.558-0.23 ± 0.529
Week 16; n= 290, 289-0.06 ± 0.808-0.21 ± 0.754
Week 24; n= 291, 285-0.08 ± 0.768-0.20 ± 0.747
Week 36; n= 286, 276-0.01 ± 0.792-0.18 ± 0.749
Week 48; n= 268, 2480.01 ± 0.798-0.18 ± 0.750
Week 52; n= 269, 233-0.01 ± 0.788-0.17 ± 0.761
SecondaryNumber of Participants With Hematology Toxicities -Randomized Phase

Number of participants with hematology toxicities has been presented. Toxicities were based on the Division of AIDS (DAIDS) grading system. Grade 1=Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Potentially life-threatening. Higher the grade, more severe the symptoms. Data has been reported for hematology parameters including Hemoglobin, Leukocytes, Neutrophils and Platelets.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Hematology Toxicities -Randomized Phase
ParticipantsParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
Hemoglobin; Grade 1618
Hemoglobin; Grade 254
Hemoglobin; Grade 350
Hemoglobin; Grade 441
Leukocytes; Grade 11910
Leukocytes; Grade 255
Leukocytes; Grade 330
Leukocytes; Grade 400
Neutrophils; Grade 12526
Neutrophils; Grade 2911
Neutrophils; Grade 3103
Neutrophils; Grade 440
Platelets; Grade 164
Platelets; Grade 227
Platelets; Grade 301
Platelets; Grade 410
SecondaryNumber of Participants With Hematology Toxicities-Continuation Phase

Number of participants with hematology toxicities has been presented. Toxicities were based on the Division of AIDS (DAIDS) grading system. Grade 1=Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Potentially life-threatening. Higher the grade, more severe the symptoms. Data has been reported for hematology parameters including Hemoglobin, Leukocytes, Neutrophils and Platelets.

Time frame:
Up to Week 295
Reported as:
Count of participants · Participants
Number of Participants With Hematology Toxicities-Continuation Phase
ParticipantsParticipants Receiving DTG in Continuation Phase
Hemoglobin; Grade 113
Hemoglobin; Grade 22
Hemoglobin; Grade 31
Hemoglobin; Grade 40
Leukocytes; Grade 123
Leukocytes; Grade 26
Leukocytes; Grade 30
Leukocytes; Grade 40
Neutrophils; Grade 121
Neutrophils; Grade 216
Neutrophils; Grade 310
Neutrophils; Grade 42
Platelets; Grade 16
Platelets; Grade 23
Platelets; Grade 31
Platelets; Grade 40
SecondaryNumber of Participants Who Discontinued Treatment Due to AEs-Randomized Phase

Number of participants who discontinued study treatment due to AEs or SAEs were summarized.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Treatment Due to AEs-Randomized Phase
ParticipantsParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
Number of Participants Who Discontinued Treatment Due to AEs-Randomized Phase818
SecondaryNumber of Participants Who Discontinued Treatment Due to AEs-Continuation Phase

Number of participants who discontinued study treatment due to AEs were summarized.

Time frame:
Up to Week 295
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Treatment Due to AEs-Continuation Phase
ParticipantsParticipants Receiving DTG in Continuation Phase
Number of Participants Who Discontinued Treatment Due to AEs-Continuation Phase9
SecondaryChange From Baseline in Fasting LDL Cholesterol at Week 24 and Week 48

Blood samples were collected from participants in fasting state to evaluate LDL cholesterol. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. Analysis was performed using multiple imputation with missing at random assumption. Only participants available at the time of evaluation were analyzed.

Time frame:
Baseline (Day 1, Pre-dose), Week 24 and Week 48
Reported as:
Mean · Millimoles per liter
Change From Baseline in Fasting LDL Cholesterol at Week 24 and Week 48
Millimoles per literParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
Week 24-0.121 ± 0.03560.050 ± 0.0378
Week 48-0.012 ± 0.03870.135 ± 0.0416
Statistical analysis
  • Participants Receiving DTG-Randomized Phase vs Participants Receiving LPV/RTV-Randomized Phase · Multiple imputation · p = 0.0010 · Mean difference (net): -0.171 · 95% CI -0.272 to -0.069Mean difference at Week 24 was calculated using multiple imputation using missing at random, adjusting for Baseline LDL cholesterol, Baseline plasma HIV-1 RNA, Baseline number of Fully Active NRTIs in the background regimen and Age
  • Participants Receiving DTG-Randomized Phase vs Participants Receiving LPV/RTV-Randomized Phase · 'Multiple imputation · p = 0.0100 · Mean difference (net): -0.147 · 95% CI -0.259 to -0.035Mean difference at Week 48 was calculated using multiple imputation using missing at random, adjusting for Baseline LDL cholesterol, Baseline plasma HIV-1 RNA, Baseline number of Fully Active NRTIs in the background regimen and Age
SecondaryChange From Baseline in Fasting Total Cholesterol/HDL Cholesterol Ratio

Blood samples were collected from participants in fasting state to evaluate total cholesterol/HDL cholesterol ratio. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. Only participants available at the time of evaluation were analyzed. Analysis was performed using multiple imputation with missing at random assumption.

Time frame:
Baseline (Day 1, Pre-dose), Week 24 and Week 48
Reported as:
Mean · Ratio
Change From Baseline in Fasting Total Cholesterol/HDL Cholesterol Ratio
RatioParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
Week 24-0.237 ± 0.06620.305 ± 0.0683
Week 48-0.084 ± 0.06930.275 ± 0.0729
Statistical analysis
  • Participants Receiving DTG-Randomized Phase vs Participants Receiving LPV/RTV-Randomized Phase · Multiple imputation · p = <0.0001 · Mean difference (net): -0.542 · 95% CI -0.729 to -0.356Estimates at Week 24 are calculated using multiple imputation using missing at random, adjusting for Baseline total cholesterol/HDL ratio, Baseline plasma HIV-1 RNA, Baseline number of Fully Active NRTIs in the background regimen and Age.
  • Participants Receiving DTG-Randomized Phase vs Participants Receiving LPV/RTV-Randomized Phase · Multiple imputation · p = 0.0004 · Mean difference (net): -0.358 · 95% CI -0.555 to -0.161Estimates at Week 48 are calculated using multiple imputation using missing at random, adjusting for Baseline total cholesterol/HDL ratio, Baseline plasma HIV-1 RNA, Baseline number of Fully Active NRTIs in the background regimen and Age.
SecondaryNumber of Participants With Maximum Post-Baseline Emergent Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol

Blood samples were collected from participants in fasting state at indicated time-points to evaluate LDL cholesterol. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. Number of participants who experienced maximum grade 2 or greater toxicity post-Baseline in fasting LDL cholesterol was summarized. Participants were graded using the Division of AIDS Table for Grading Severity of Adult and Pediatric Adverse Events. Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=potentially life-threatening. Higher the grade, more severe the symptoms.

Time frame:
Up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Maximum Post-Baseline Emergent Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol
ParticipantsParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
Number of Participants With Maximum Post-Baseline Emergent Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol520
SecondaryNumber of Participants With Maximum Post-Baseline Emergent Grade 2 or Greater Drug-related Diarrhea

Number of participants who experienced maximum grade 2 or greater toxicity post-Baseline in drug-related diarrhea was summarized. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. Participants were graded using the Division of AIDS Table for Grading Severity of Adult and Pediatric Adverse Events. Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=potentially life-threatening. Higher the grade, more severe the symptoms.

Time frame:
Week 24 and Week 48
Reported as:
Count of participants · Participants
Number of Participants With Maximum Post-Baseline Emergent Grade 2 or Greater Drug-related Diarrhea
ParticipantsParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
Week 24122
Week 48123
SecondaryChange From Baseline in Gastrointestinal Symptom Rating Scale (GSRS) Score

The GSRS is a disease-specific instrument of 15 items combined into five symptom clusters depicting Reflux, Abdominal pain, Indigestion, Diarrhea and Constipation. The scale ranges from 1= no discomfort to 7= very severe discomfort for each symptom cluster. Higher scores show greater severity of symptoms. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. The analysis was performed using Last Observation Carried Forward (LOCF) dataset. In the LOCF dataset, missing values were carried forward from the previous, non-missing available on-treatment assessment.

Time frame:
Baseline (Day 1, Pre-dose), Week 4, Week 24, Week 48
Reported as:
Median · Scores on a scale
Change From Baseline in Gastrointestinal Symptom Rating Scale (GSRS) Score
Scores on a scaleParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
Diarrhea Syndrome Score; Week 4; n= 303, 3050.00 (-0.33 to 0.00)0.00 (0.00 to 1.33)
Diarrhea Syndrome Score; Week 24; n= 305, 3060.00 (-0.33 to 0.00)0.00 (0.00 to 1.00)
Diarrhea Syndrome Score; Week 48; n= 305, 3060.00 (-0.33 to 0.00)0.00 (0.00 to 0.67)
Indigestion Syndrome Score; Week 4; n=305, 3060.00 (-0.25 to 0.00)0.00 (0.00 to 0.75)
Indigestion Syndrome Score; Week 24; n= 306, 3070.00 (-0.25 to 0.00)0.00 (-0.25 to 0.50)
Indigestion Syndrome Score; Week 48; n= 306, 3070.00 (-0.50 to 0.00)0.00 (-0.25 to 0.50)
Constipation Score; Week 4; n= 305, 3050.00 (0.00 to 0.00)0.00 (0.00 to 0.33)
Constipation Score; Week 24; n= 306, 3060.00 (0.00 to 0.00)0.00 (0.00 to 0.33)
Constipation Score; Week 48; n= 306, 3060.00 (0.00 to 0.00)0.00 (0.00 to 0.33)
Abdominal pain Score; Week 4; n= 305, 3060.00 (-0.33 to 0.00)0.00 (0.00 to 0.67)
Abdominal pain Score; Week 24; n= 306, 3070.00 (-0.33 to 0.00)0.00 (-0.33 to 0.67)
Abdominal pain Score; Week 48; n= 306, 3070.00 (-0.67 to 0.00)0.00 (0.00 to 0.33)
Reflux Score; Week 4; n= 305, 3060.00 (0.00 to 0.00)0.00 (0.00 to 0.50)
Reflux Score; Week 24; n= 306, 3070.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
Reflux Score; Week 48; n= 306, 3070.00 (0.00 to 0.00)0.00 (0.00 to 0.50)
SecondaryChange From Baseline in Treatment Satisfaction, Using the HIV-Treatment Satisfaction Questionnaire (HIVTSQ) Score

The HIVTSQ is a self-reported scales that measure overall satisfaction with treatment. The score ranges from 0-10. The higher the score, the greater the improvement in treatment satisfaction as compared to the past few weeks. A smaller score represents a decline in treatment satisfaction compared to the past few weeks. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. The analysis was performed using LOCF dataset. In the LOCF dataset, missing values were carried forward from the previous, non-missing available on-treatment assessment.

Time frame:
Baseline (Day 1, Pre-dose), Week 4, Week 24, Week 48
Reported as:
Median · Scores on a scale
Change From Baseline in Treatment Satisfaction, Using the HIV-Treatment Satisfaction Questionnaire (HIVTSQ) Score
Scores on a scaleParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
Week 4; n= 304, 3063.4 (0.0 to 11.5)2.0 (0.0 to 10.0)
Week 24; n= 305, 3075.0 (0.0 to 13.0)3.0 (0.0 to 12.0)
Week 48; n= 305, 3075.0 (0.0 to 14.0)3.0 (0.0 to 11.0)
SecondaryNumber of Participants Showing Adherence With Treatment, Using the Morisky 8-Item Medication Adherence Scale (MMAS-8)

Treatment compliance was evaluated through MMAS-8. It is an eight-item self-reported measure of medication-taking behavior. The score ranges from 0-8 where scores of 8 indicate high or near perfect adherence, and scores of less than 6 indicate poor or inadequate adherence on the MMAS-8 scale. Number of participants showing low, medium and high adherence to treatment are presented. Low adherence is a score 0-5.75, medium adherence is a score of 6-7.75 and high adherence is a score of 8. The analysis was performed using LOCF dataset. In the LOCF dataset, missing values were carried forward from the previous, non-missing available on-treatment assessment.

Time frame:
Baseline (Day 1, Pre-dose), Week 4, Week 24 and Week 48
Reported as:
Count of participants · Participants
Number of Participants Showing Adherence With Treatment, Using the Morisky 8-Item Medication Adherence Scale (MMAS-8)
ParticipantsParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized Phase
Baseline (Day 1, Pre-dose); low; n= 309, 3127075
Baseline (Day 1, Pre-dose); medium; n= 309, 312102100
Baseline (Day 1, Pre-dose); high; n= 309, 312137137
Week 4; low; n= 306, 3061737
Week 4; medium; n= 306, 3068180
Week 4; high n= 306, 306208189
Week 24; low; n= 307, 3072539
Week 24; medium; n= 307, 3078376
Week 24; high; n= 307,307199192
Week 48; low; n= 307, 3072852
Week 48; medium; n= 307, 3077482
Week 48; high; n= 307, 307205173

Adverse events

Collected over All-cause mortality, Serious adverse events (SAEs) and non-SAEs were collected up to Week 52 for Randomized Phase; up to Week 295 for Continuation Phase and up to Week 348 for Randomized Phase+Continuation Phase.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Participants Receiving DTG-Randomized Phase2/314 (0.6%)20/314 (6.4%)155/314 (49.4%)
Participants Receiving LPV/RTV-Randomized Phase3/310 (1%)20/310 (6.5%)202/310 (65.2%)
Participants Receiving DTG-Continuation Phase3/274 (1.1%)29/274 (10.6%)150/274 (54.7%)
DTG in Randomized Phase Followed by Continuation Phase5/314 (1.6%)47/314 (15%)218/314 (69.4%)
LPV/RTV-Randomized Phase Followed by DTG in Continuation Phase3/310 (1%)20/310 (6.5%)213/310 (68.7%)
Most frequent serious events
Showing 10 of 67
Most frequent serious events
EventParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized PhaseParticipants Receiving DTG-Continuation PhaseDTG in Randomized Phase Followed by Continuation PhaseLPV/RTV-Randomized Phase Followed by DTG in Continuation Phase
PneumoniaInfections and infestations3/3145/3100/2743/3145/310
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/3140/3103/2745/3140/310
Tibia fractureInjury, poisoning and procedural complications0/3140/3103/2743/3140/310
AnaemiaBlood and lymphatic system disorders2/3142/3101/2743/3142/310
Cerebral toxoplasmosisInfections and infestations1/3142/3100/2741/3142/310
Immune reconstitution inflammatory syndromeImmune system disorders0/3142/3100/2740/3142/310
Pericardial effusionCardiac disorders1/3140/3101/2742/3140/310
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/3140/3101/2742/3140/310
Drug-induced liver injuryHepatobiliary disorders1/3140/3101/2742/3140/310
HypokalaemiaMetabolism and nutrition disorders1/3140/3101/2742/3140/310
Most frequent other events
Showing 10 of 50
Most frequent other events
EventParticipants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized PhaseParticipants Receiving DTG-Continuation PhaseDTG in Randomized Phase Followed by Continuation PhaseLPV/RTV-Randomized Phase Followed by DTG in Continuation Phase
DiarrhoeaGastrointestinal disorders28/314105/31019/27438/314105/310
Upper respiratory tract infectionInfections and infestations45/31443/31065/27483/31443/310
HeadacheNervous system disorders24/31416/31013/27437/31416/310
NauseaGastrointestinal disorders10/31430/3105/27414/31430/310
CoughRespiratory, thoracic and mediastinal disorders14/31410/31016/27427/31410/310
Back painMusculoskeletal and connective tissue disorders0/3140/31019/27424/3147/310
Lower respiratory tract infectionInfections and infestations13/31414/31016/27422/31414/310
VomitingGastrointestinal disorders5/31421/3102/2746/31421/310
ArthralgiaMusculoskeletal and connective tissue disorders6/3147/31012/27420/3147/310
DyspepsiaGastrointestinal disorders10/31412/3109/27419/31412/310

Baseline characteristics

Baseline Characteristic data are reported for members of the ITT-E Population which comprised of all participants who received at least one dose of study medication.

Age, Continuous
Age, Continuous(Years)Participants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized PhaseTotal
Mean37.5 ± 9.1338.7 ± 9.3538.1 ± 9.25
Sex: Female, Male
Sex: Female, Male(Participants)Participants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized PhaseTotal
Female116103219
Male196209405
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Participants Receiving DTG-Randomized PhaseParticipants Receiving LPV/RTV-Randomized PhaseTotal
Race, customized — American Indian or Alaska native425395
Race, customized — Asian- Central/South Asian Heritage101
Race, customized — Asian - East Asian Heritage213152
Race, customized — Asian - South East Asian Heritage282553
Race, customized — White - Arabic/North African Heritage202
Race, customized — White - White/Caucasian/European Heritage8890178
Race, customized — Mixed White Race011
Race, customized — Black or African American Heritage130112242
08

Study locations

59 sites
  • GSK Investigational Site
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1405CKC, Argentina
  • GSK Investigational Site
    Ciudad de Buenos Aires, Buenos Aires C1202ABB, Argentina
  • GSK Investigational Site
    Rosario, Santa Fe 2000, Argentina
  • GSK Investigational Site
    Buenos Aires, 1141, Argentina
  • GSK Investigational Site
    Buenos Aires, C1221ADC, Argentina
  • GSK Investigational Site
    Ciudad Autónoma de Buenos Aires, C1426ABP, Argentina
  • GSK Investigational Site
    Córdoba, 5000, Argentina
  • GSK Investigational Site
    Salvador, Bahía 40110-010, Brazil
  • GSK Investigational Site
    Sao Paulo, São Paulo 01246-090, Brazil
  • GSK Investigational Site
    Rio de Janeiro, 21045900, Brazil
  • GSK Investigational Site
    São Paulo, 04121-000, Brazil
  • GSK Investigational Site
    Puente Alto - Santiago, Región Metro De Santiago 8207257, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 8330074, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 8900088, Chile
  • GSK Investigational Site
    Santiago, 8360159, Chile
  • GSK Investigational Site
    Guangzhou, Guangdong 510060, China
  • GSK Investigational Site
    Beijing, 100015, China
  • GSK Investigational Site
    Beijing, 100069, China
  • GSK Investigational Site
    Shanghai, 201508, China
  • GSK Investigational Site
    Bogota, 111311, Colombia
  • GSK Investigational Site
    Bogota, 5600520, Colombia
  • GSK Investigational Site
    Nairobi, 00100, Kenya
  • GSK Investigational Site
    Guadalajara, Jalisco 44280, Mexico
  • GSK Investigational Site
    Distrito Federal, 06470, Mexico
  • GSK Investigational Site
    Mexico City, 03720, Mexico
  • GSK Investigational Site
    Mexico, 14000, Mexico
  • GSK Investigational Site
    Callao, Callao 02, Peru
  • GSK Investigational Site
    Lima, 1, Peru
  • GSK Investigational Site
    Lima, 32, Peru
  • GSK Investigational Site
    Lima, Lima 31, Peru
  • GSK Investigational Site
    Bucharest, 021105, Romania
  • GSK Investigational Site
    Bucharest, 030303, Romania
  • GSK Investigational Site
    Cluj-Napoca, 400348, Romania
  • GSK Investigational Site
    Constanta, 900708, Romania
  • GSK Investigational Site
    Targu Mures, 540394, Romania
  • GSK Investigational Site
    Barnaul, 656010, Russian Federation
  • GSK Investigational Site
    Ekaterinburg, 620149, Russian Federation
  • GSK Investigational Site
    Kazan, 420061, Russian Federation
  • GSK Investigational Site
    Kemerovo, 650056, Russian Federation
  • GSK Investigational Site
    Krasnodar, 350015, Russian Federation
  • GSK Investigational Site
    Moscow, 105275, Russian Federation
  • GSK Investigational Site
    Moscow, 129110, Russian Federation
  • GSK Investigational Site
    Smolensk, 214006, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 190103, Russian Federation
  • GSK Investigational Site
    Toliyatti, 445846, Russian Federation
  • GSK Investigational Site
    Soweto, Gauteng 2013, South Africa
  • GSK Investigational Site
    Bloemfontein, 9301, South Africa
  • GSK Investigational Site
    Durban, 4001, South Africa
  • GSK Investigational Site
    Observatory, Cape Town, 7925, South Africa
  • GSK Investigational Site
    Westdene, 2092, South Africa
  • GSK Investigational Site
    Bangkok, 10330, Thailand
  • GSK Investigational Site
    Chiang Mai, 50200, Thailand
  • GSK Investigational Site
    Khon Kaen, 40002, Thailand
  • GSK Investigational Site
    Nonthaburi, 11000, Thailand
  • GSK Investigational Site
    Ratchatewi, 10400, Thailand
  • GSK Investigational Site
    Kyiv, 03115, Ukraine
  • GSK Investigational Site
    Odessa, 65031, Ukraine
  • GSK Investigational Site
    Vinnytsia, 21021, Ukraine
  • GSK Investigational Site
    Zaporizhzhya, 69006, Ukraine
09

References and documents

Publications

  • Aboud M, Kaplan R, Lombaard J, Zhang F, Hidalgo JA, Mamedova E, Losso MH, Chetchotisakd P, Brites C, Sievers J, Brown D, Hopking J, Underwood M, Nascimento MC, Punekar Y, Gartland M, Smith K. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. Lancet Infect Dis. 2019 Mar;19(3):253-264. doi: 10.1016/S1473-3099(19)30036-2. Epub 2019 Feb 4. PubMed 30732940 ↗
  • Underwood M, Horton J, Nangle K, Hopking J, Smith K, Aboud M, Wynne B, Sievers J, Stewart EL, Wang R. Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study. Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0164321. doi: 10.1128/AAC.01643-21. Epub 2021 Oct 25. Erratum In: Antimicrob Agents Chemother. 2023 Mar 16;67(3):e0032622. doi: 10.1128/aac.00326-22. PubMed 34694877 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on ViiV's data sharing criteria can be found at: https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · viivhealthcare.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2014 to primary completion in Aug 2017, 31 months.

Results were first posted in Jul 2019, 1 year 11 months after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 31 months is above that.

Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2014
First posted
Aug 28, 2014
StartActual
Dec 11, 2014
Primary completionActual
Aug 2, 2017
CompletionActual
Feb 14, 2022
Results first posted
Jul 12, 2019
Last update
Mar 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02227238
Lead sponsor
ViiV Healthcare
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 28, 2014
Start date
Dec 11, 2014
Primary completion
Aug 2, 2017
Completion
Feb 14, 2022
Results posted
Jul 12, 2019
Last update
Mar 13, 2023

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dolutegravir

Start the discussion